This page uses content from Wikipedia and is licensed under CC BY-SA.

DSP-2230

DSP-2230
DSP-2230.svg
Clinical data
Routes of
administration
By mouth
Identifiers
CAS Number
ChEMBL
Chemical and physical data
FormulaC20H20F3N5O2
Molar mass419.408 g/mol g·mol−1
3D model (JSmol)

DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]

See also

References

  1. ^ a b Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662. ISSN 1945-3477.
  2. ^ a b Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.

External links